BCDA - יחס חוב להיוון בספרים BioCardia Inc.

BioCardia, Inc. (BCDA) holds patents for cell therapy systems, ensuring a long-term B2B sales cycle. The dynamic debt-to-book capitalization ratio visualizes the capital structure, where the 0.11 mark indicates the current state. Innovative Helix systems make the myocardial drug delivery method unique; however, the lack of commercial products forces the company to rely on remaining raised investments.

It is critically important for BioCardia, Inc. (BCDA) to control development costs for cardiac cell therapies. This metric compares total liabilities to the book value of equity, measuring the company's degree of financial autonomy. By analyzing the debt-to-capitalization ratio, an investor assesses the risk of bankruptcy amid a high cash burn. Current price action confirms the stability of the liability structure, which guarantees a margin of safety until the completion of clinical trials.